Rheumatoid Arthritis Clinical Trial
Official title:
Persona® TM Tibia Clinical Outcomes Study: Prospective Multicenter Study of the Persona® Trabecular Metal Tibia
Verified date | February 2023 |
Source | Zimmer Biomet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to evaluate clinical performance for the commercially available Persona TM Tibia used in primary cementless tibia total knee arthroplasty.
Status | Completed |
Enrollment | 161 |
Est. completion date | November 30, 2022 |
Est. primary completion date | November 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patient is at least 18 years of age. 2. Patient qualifies for a primary cementless tibia total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following: 1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis. 2. Collagen disorders and/or avascular necrosis of the femoral condyle. 3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy. 4. Moderate valgus, varus, or flexion deformities. 5. The salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee. 3. Patient has participated in the study-related Informed Consent process. 4. Patient is willing and able to provide written Informed Consent by signing and dating the IRB approved Informed Consent Form. 5. Patient is willing and able to complete scheduled study procedures and follow-up evaluations as described in the Informed Consent Form. 6. Independent of study participation, patient is a candidate for commercially available cementless Persona TM tibial knee component, implanted in accordance with product labeling. Exclusion Criteria: 1. Previous history of infection in the affected joint. 2. Active local or systemic infection that may affect the prosthetic joint. 3. Insufficient bone stock on femoral or tibial surfaces. 4. Skeletal immaturity. 5. Neuropathic arthropathy. 6. Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb. 7. A stable, painless arthrodesis in a satisfactory functional position. 8. Severe instability secondary to the absence of collateral ligament integrity. 9. Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin. 10. Patient has previously received partial or total knee arthroplasty for the ipsilateral knee. 11. Patient is currently participating in any other surgical intervention studies or pain management studies. 12. Patient is known to be pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.). 13. Patient has a known or suspected sensitivity or allergy to one or more of the implant materials. |
Country | Name | City | State |
---|---|---|---|
United States | Woods Mill Orthopedics, Ltd | Chesterfield | Missouri |
United States | Hawaii Pacific Health | Honolulu | Hawaii |
United States | Henry County Orthopedics and Sports Medicine | New Castle | Indiana |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Pinehurst Surgical Clinic | Pinehurst | North Carolina |
United States | LA BioMed at Harbor-UCLA Medical Center | Torrance | California |
United States | Cornerstone Orthopaedics & Sports Medicine, P.C. | Wheat Ridge | Colorado |
Lead Sponsor | Collaborator |
---|---|
Zimmer Biomet |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Radiograph assessment of progressive tibial radiolucencies | Progressive Tibial Radiolucency will be derived in accordance with the following definitions:
Absent: No evidence of an increase in either radiolucency extent (number of zones involved) or measured width within a zone. Present: Presence of either: An increase in the number of zones with a measured Tibial Radiolucency, OR An increase in the measured Tibial Radiolucency width within a zone of >0.5 mm. |
2 years | |
Secondary | Oxford Knee Score | The Oxford Knee Score is a patient completed 12 question metric to rate a patient's knee pain and function using an ordinal 0 - 4 point scale. The total score is obtained by calculating the sum of the 12 items. The minimum score is 0 and the maximum score is 48 points. | 2 years | |
Secondary | Revision Rate | Rate of the number of revisions for any reason | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |